We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 20, 2017

Outcomes of HER2-Positive Patients With Newly Diagnosed Stage IV or Recurrent Breast Cancer Undergoing First-Line Trastuzumab-Based Therapy

Clinical Breast Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
Patterns of Care and Clinical Outcomes of HER2-Positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-Line Trastuzumab-Based Therapy: A Multicenter Retrospective Cohort Study
Clin. Breast Cancer 2017 Apr 10;[EPub Ahead of Print], M Lambertini, AR Ferreira, A Di Meglio, et al

Further Reading